Dr. Reddys Laboratories (RDY) Stock Research, Analysis & News

Quick Analysis on Dr. Reddys Laboratories (RDY) Stock as of November 23, 2014

Previous Closing Price $56.99 is above 50 day moving average of $52.18
Previous Closing Price $56.99 is above 200 day moving average of $46.76
The Stock pays a dividend of 0.53%
The closing price $56.99 is less than -7.70% away from its one year target price of $52.60
Current Short Ratio 12.10 is great than 1
(See more information about Dr. Reddys Laboratories (RDY) Stock below)

Dr. Reddys Laboratories (RDY) Stock Profile Summary

Dr. Reddys Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Dr. Reddys Laboratories (RDY) Stock Key Statistics Research and Analysis as of November 23, 2014

Stock ExchangeNYSE
Market Capitalization$9.806B
Trade Volume (Average Trading Volume)144,482 (230,829)
Price/Sales4.28
Price/Book6.07
P/E27.10
Earning/Share$2.103
Next Year EPS Estimate$2.15
Previous Closing Price$56.99
50 Day Price Moving Average$52.18
200 Day Price Moving Average$46.76
Dividend Yield0.53%
1 yr Target Price$52.60
Ex-Dividend DateAug 1
Short Ratio12.10
EBITDA$558.2M

Dr. Reddys Laboratories (RDY) Stock Competitor Research and Analysis

Teva Pharmaceutical Industries Limited (TEVA)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Stock Research on Dr. Reddys Laboratories (RDY)

Latest Market News on Dr. Reddys Laboratories (RDY)


Click here to find the latest news on Dr. Reddys Laboratories (RDY)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Teva Pharmaceutical Industries Limited (TEVA)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)